Back to Search
Start Over
Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)
- Source :
- Allergy, 76(1), 90-113. Wiley-Blackwell, Allergy, 76(1), 90. Blackwell Publishing Ltd
- Publication Year :
- 2021
-
Abstract
- Therapeutic advances using targeted biologicals and small-molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune, and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic, or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in nononcological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in nononcological settings such as cardiovascular disease, obesity, and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.
- Subjects :
- Adoptive cell transfer
Disease
medicine.disease_cause
T-Lymphocytes, Regulatory
FOOD ALLERGY
adoptive cell therapies
Autoimmunity
CONFERS PROTECTION
0302 clinical medicine
allergy
autoimmunity
CAR-Treg cells
immunoregulation
Immunology and Allergy
LYMPHOCYTE-ACTIVATION
EXPERIMENTAL COLITIS
10177 Dermatology Clinic
MOUSE MODEL
CAR‐
medicine.anatomical_structure
1107 Immunology
2723 Immunology and Allergy
Allergen immunotherapy
T cell
Immunology
DNA METHYLTRANSFERASE
610 Medicine & health
Autoimmune Diseases
03 medical and health sciences
Immune system
medicine
Hypersensitivity
Humans
ADOPTIVE TRANSFER
2403 Immunology
TRANSCRIPTION FACTOR FOXP3
business.industry
Immunopharmacology
Asthma
Transplantation
ATTENUATES AIRWAY INFLAMMATION
ORAL TOLERANCE
030228 respiratory system
10033 Clinic for Immunology
business
Treg cells
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 01054538
- Database :
- OpenAIRE
- Journal :
- Allergy, 76(1), 90-113. Wiley-Blackwell, Allergy, 76(1), 90. Blackwell Publishing Ltd
- Accession number :
- edsair.doi.dedup.....4ced1134a28d5ad99c388f7c7e59195c